Categories Consumer, Earnings

KB Home reports mixed results for Q3

KB Home (NYSE: KBH) reported mixed results for third quarter 2019. Earnings of $0.73 per share surpassed the consensus estimates, while revenue of $1.16 billion missed the analysts’ views. Analysts had expected the homebuilder to post earnings of $0.66 per share on revenue of $1.17 billion in the third quarter. KB Home stock was down about 2% in the extended trading session.

Shares of KB Home hit a new 52-week high ($32.48) today as the analyst firm Raymond James upgraded KBH stock to “outperform” and on the strong sales of the newly built homes in the month of August.

KB Home (KBH) reports mixed results for Q3 2019; stock reached new 52-week high today

Earnings decreased to $68 million or $0.73 per share in the three months ended August 31, 2019 from $87 million or $0.87 per share in the prior-year period. Revenue decreased 5% year-over-year.

Net orders for the third quarter grew 24% to 3,325, while backlog rose 14% to 6,230 homes. KB Home delivered 3,022 homes in the four regions during the third quarter compared to 2,988 homes in the third quarter of 2018.

“With year-over-year growth in both revenues and gross profit margin anticipated for our fourth quarter, we are on track for a strong finish to 2019, the third year of our Returns-Focused Growth Plan. We expect to continue to grow our community count in 2020, and, together with our solid pace and $2.3 billion backlog, we believe we are well positioned for an excellent start to the new year,” said CEO Jeffrey Mezger.

KB Home’s rival Toll Brothers (NYSE: TOL) reported its third quarter 2019 results last month. While the company topped Street’s estimates for the quarter, it reported a drop in gross margin and orders.

KBH stock had surged 69% so far in this year and 28% in the past 52-weeks.

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top